Search - tctmd.com

Displaying 41 - 60 of 62

Sort: Relevancy | Date

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

Todd Neale

September 22, 2018

News Daily News

FDA Approves Resolute Onyx, Billed as Slimmest Stent Yet on US Market

Yael L. Maxwell

February 26, 2018

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

L.A. McKeown

July 29, 2015

News Daily News

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

L.A. McKeown

July 29, 2015

News Features

医院、介入科医生有机会避免患者不必要的再次入院

July 28, 2015

News Features

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

July 28, 2015

Presentation

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

Presenter: Mohamed Abdel-Wahab

July 23, 2015

News Daily News

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

L.A. McKeown

July 01, 2015

News Daily News

RIBS IV：EES 支架内再狭窄治疗效果超越 DCB

L.A. McKeown

July 01, 2015

News Daily News

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

Yael L. Maxwell

June 26, 2015

News Daily News

LEVANT 2：DCB 治疗股腘动脉疾病的 1 年随访结果优于标准球囊成形术

Yael L. Maxwell

June 26, 2015

Advertisement

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

TALENT: Indian-Made Supraflex DES Stands Up Well Against Xience in All-Comers

FDA Approves Resolute Onyx, Billed as Slimmest Stent Yet on US Market

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

TCTMD’s Top 10 Most Popular Stories for August 2016

斑块消退证据对于联合使用他汀类药物与依泽替米贝的病例提出了支持

Evidence of Plaque Regression Bolsters Case for Combining Ezetimibe With Statin

医院、介入科医生有机会避免患者不必要的再次入院

Opportunities Exist for Hospitals, Interventionalists to Stave Off Unnecessary Readmissions

Incidence and Predictors of Unplanned Non-TLR Up to 3 Years After DES Implantation

RIBS IV: EES Surpass DCB for Treatment of In-Stent Restenosis

RIBS IV：EES 支架内再狭窄治疗效果超越 DCB

LEVANT 2: DCB Beats Standard Balloon Angioplasty at 1 Year in Femoropopliteal Disease

LEVANT 2：DCB 治疗股腘动脉疾病的 1 年随访结果优于标准球囊成形术

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content